- Home
- NEPH vs LPCN Comparison
NEPH vs LPCN Comparison
Compare NEPH & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- LPCN
- Stock Information
- Founded
- NEPH 1997
- LPCN 1997
- Country
- NEPH United States
- LPCN United States
- Employees
- NEPH N/A
- LPCN N/A
- Industry
- NEPH Medical/Dental Instruments
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NEPH Health Care
- LPCN Health Care
- Exchange
- NEPH Nasdaq
- LPCN Nasdaq
- Market Cap
- NEPH 16.8M
- LPCN 16.1M
- IPO Year
- NEPH 2004
- LPCN N/A
- Fundamental
- Price
- NEPH $1.86
- LPCN $3.10
- Analyst Decision
- NEPH Buy
- LPCN Strong Buy
- Analyst Count
- NEPH 1
- LPCN 1
- Target Price
- NEPH $5.00
- LPCN $10.00
- AVG Volume (30 Days)
- NEPH 12.1K
- LPCN 10.3K
- Earning Date
- NEPH 05-08-2025
- LPCN 05-08-2025
- Dividend Yield
- NEPH N/A
- LPCN N/A
- EPS Growth
- NEPH N/A
- LPCN N/A
- EPS
- NEPH 0.01
- LPCN N/A
- Revenue
- NEPH $14,162,000.00
- LPCN $11,198,144.00
- Revenue This Year
- NEPH $9.23
- LPCN N/A
- Revenue Next Year
- NEPH $12.99
- LPCN N/A
- P/E Ratio
- NEPH $277.38
- LPCN N/A
- Revenue Growth
- NEPH N/A
- LPCN N/A
- 52 Week Low
- NEPH $1.36
- LPCN $2.75
- 52 Week High
- NEPH $2.55
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- NEPH 51.99
- LPCN 46.56
- Support Level
- NEPH $1.66
- LPCN $2.82
- Resistance Level
- NEPH $2.05
- LPCN $3.27
- Average True Range (ATR)
- NEPH 0.11
- LPCN 0.23
- MACD
- NEPH -0.01
- LPCN 0.01
- Stochastic Oscillator
- NEPH 35.71
- LPCN 58.92
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.